Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: Angiogenesis. 2014 Feb 26;17(3):661–673. doi: 10.1007/s10456-014-9422-9

Fig. 6.

Fig. 6

Examination of the effect of chemotherapeutic switching on survival of mice implanted with the resistant variant 7SD. a The use of MTD topotecan regimen (while maintaining pazopanib) translated into minimal improvement in survival in mice implanted with 7SD variant cell line. b Switching to CPT11 either in MTD or metronomic regimen plus pazopanib showed minimal efficacy in the survival. c Switching of the antiangiogenic component of the combination therapy to either DC101 or sunitinib in combination with metronomic topotecan failed to show the significant effect in survival previously noted in the SKOV-3-13 chemo-sensitive model. (n = 5 mice for all groups P < 0.05)